Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus
- PMID: 22674976
- PMCID: PMC3421718
- DOI: 10.1128/JVI.00147-12
Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus
Abstract
Compared to seasonal influenza viruses, the 2009 pandemic H1N1 (pH1N1) virus caused greater morbidity and mortality in children and young adults. People over 60 years of age showed a higher prevalence of cross-reactive pH1N1 antibodies, suggesting that they were previously exposed to an influenza virus or vaccine that was antigenically related to the pH1N1 virus. To define the basis for this cross-reactivity, ferrets were infected with H1N1 viruses of variable antigenic distance that circulated during different decades from the 1930s (Alaska/35), 1940s (Fort Monmouth/47), 1950s (Fort Warren/50), and 1990s (New Caledonia/99) and challenged with 2009 pH1N1 virus 6 weeks later. Ferrets primed with the homologous CA/09 or New Jersey/76 (NJ/76) virus served as a positive control, while the negative control was an influenza B virus that should not cross-protect against influenza A virus infection. Significant protection against challenge virus replication in the respiratory tract was observed in ferrets primed with AK/35, FM/47, and NJ/76; FW/50-primed ferrets showed reduced protection, and NC/99-primed ferrets were not protected. The hemagglutinins (HAs) of AK/35, FM/47, and FW/50 differ in the presence of glycosylation sites. We found that the loss of protective efficacy observed with FW/50 was associated with the presence of a specific glycosylation site. Our results suggest that changes in the HA occurred between 1947 and 1950, such that prior infection could no longer protect against 2009 pH1N1 infection. This provides a mechanistic understanding of the nature of serological cross-protection observed in people over 60 years of age during the 2009 H1N1 pandemic.
Figures

Similar articles
-
Humans and ferrets with prior H1N1 influenza virus infections do not exhibit evidence of original antigenic sin after infection or vaccination with the 2009 pandemic H1N1 influenza virus.Clin Vaccine Immunol. 2014 May;21(5):737-46. doi: 10.1128/CVI.00790-13. Epub 2014 Mar 19. Clin Vaccine Immunol. 2014. PMID: 24648486 Free PMC article.
-
Sequential Infection in Ferrets with Antigenically Distinct Seasonal H1N1 Influenza Viruses Boosts Hemagglutinin Stalk-Specific Antibodies.J Virol. 2015 Nov 11;90(2):1116-28. doi: 10.1128/JVI.02372-15. Print 2016 Jan 15. J Virol. 2015. PMID: 26559834 Free PMC article.
-
Classical swine H1N1 influenza viruses confer cross protection from swine-origin 2009 pandemic H1N1 influenza virus infection in mice and ferrets.Virology. 2010 Dec 5;408(1):128-133. doi: 10.1016/j.virol.2010.09.009. Virology. 2010. PMID: 20926110 Free PMC article.
-
Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.J Virol. 2015 Jul;89(14):7224-34. doi: 10.1128/JVI.00585-15. Epub 2015 May 6. J Virol. 2015. PMID: 25948745 Free PMC article.
-
Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses.Sci Transl Med. 2013 May 29;5(187):187ra70. doi: 10.1126/scitranslmed.3005996. Sci Transl Med. 2013. PMID: 23720581 Free PMC article.
Cited by
-
Adjuvanted Influenza Vaccines Elicits Higher Antibody Responses against the A(H3N2) Subtype than Non-Adjuvanted Vaccines.Vaccines (Basel). 2020 Nov 25;8(4):704. doi: 10.3390/vaccines8040704. Vaccines (Basel). 2020. PMID: 33255600 Free PMC article.
-
Impaired heterologous immunity in aged ferrets during sequential influenza A H1N1 infection.Virology. 2014 Sep;464-465:177-183. doi: 10.1016/j.virol.2014.07.013. Epub 2014 Aug 1. Virology. 2014. PMID: 25086242 Free PMC article.
-
Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age.Hum Vaccin Immunother. 2014;10(5):1195-203. doi: 10.4161/hv.28313. Epub 2014 Mar 10. Hum Vaccin Immunother. 2014. PMID: 24614078 Free PMC article.
-
Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques.J Virol. 2013 May;87(10):5512-22. doi: 10.1128/JVI.03030-12. Epub 2013 Mar 6. J Virol. 2013. PMID: 23468501 Free PMC article.
-
Humans and ferrets with prior H1N1 influenza virus infections do not exhibit evidence of original antigenic sin after infection or vaccination with the 2009 pandemic H1N1 influenza virus.Clin Vaccine Immunol. 2014 May;21(5):737-46. doi: 10.1128/CVI.00790-13. Epub 2014 Mar 19. Clin Vaccine Immunol. 2014. PMID: 24648486 Free PMC article.
References
-
- Baum EZ, et al. 2003. A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding. Antivir. Res. 59:13–22 - PubMed
-
- Belser JA, Szretter KJ, Katz JM, Tumpey TM. 2009. Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses. Adv. Virus Res. 73:55–97 - PubMed
-
- Bishop JF, Murnane MP, Owen R. 2009. Australia's winter with the 2009 pandemic influenza A (H1N1) virus. N. Engl. J. Med. 361:2591–2594 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources